Breast cancer drug IBRANCE® under Real-World watch in korea

NCT ID NCT03445637

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how safe and effective the drug IBRANCE® is for women with advanced breast cancer when used in everyday medical practice. Researchers tracked 552 women in Korea for side effects and how well the drug worked. The goal was to gather real-world information to support the drug's approved use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib (IBRANCE®)
What this could lead to: If successful, this study could confirm that IBRANCE® is safe and effective in real-world use for advanced breast cancer patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only included Korean women, so findings may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM

Contacts and locations

Locations

Pfizer

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.